CVRx Q3 2025 revenue $14.7M (+10% YoY), net loss $12.9M; CMS approves favorable CPT codes for 2026

CVRx, Inc.

2025-Q3 EPS reported -$1.59 vs consensus -$0.51 ▼ miss (-210.9%)

Total revenue $14.7M, up 10% YoY; U.S. revenue $13.5M (+10%); Europe revenue $1.2M (+12%).
Net loss $12.9M ($0.49/share) vs $13.1M ($0.57/share) in Q3 2024; per-share loss improved.
U.S. active implanting centers reached 250, up 20% year-over-year.
CMS finalized Category I CPT codes for Barostim, improving patient access and removing adoption barriers.
FY2025 guidance: revenue $55.6M-$56.6M (narrowed from $55M-$57M), gross margin 85%-86% (raised from 83%-84%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.